---

27. Neonatal platelet activation in preeclampsia.
2001;7:29-32. Clin Appl Thromb Hemost. 1.332
B. Klein, A. Faridi, B. K. Amo-Takyi, L. Heilmann, G.-F.v. Tempelhoff, W. Rath.

---

26. Phospholipid-Antikörper und andere hämostaseologische Veränderungen bei Patientinnen mit früher schwerer Präeklampsie oder HELLP-Syndrom in der Anamnese.
2000;60:95-100. Geburtshilfe Frauenheilkd. 0.823
L. Heilmann, D.M. Schneider, G -F.v. Tempelhoff, S. Kuse.

---

25. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP–Syndrome.
2000;100:363-5. Thromb Res. 2.440
G.-F.v. Tempelhoff, L. Heilmann, E. Spanuth, E. Kunzmann, G. Hommel.

---

24. Association between blood rheology, thrombosis and cancer survival in patients with gynaecologic malignancy.
2000;22:107-30. Clin Hemorheol Microcirc. 3.398
G.-F.v. Tempelhoff, L. Heilmann, F. Niemann, G. Hommel.

---

23. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial.
2000;16:815-24.Int J Oncol. 2.399
G.-F.v. Tempelhoff, J. Harenberg, F. Niemann, G. Hommel, C. J. Kirkpatrick, L. Heilmann.

---

22. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: Efficacy, safety and follow – up.
1998;4:268-273. Clin Appl Thromb Hemost. 1.332
L. Heilmann, G.-F. v. Tempelhoff , C.J. Kirkpatrick, D.M. Schneider, CH. Berg, G. Hommel.

---

21. Die erworbene Resistenz gegen aktiviertes Protein C in der Schwangerschaft.
1998;202:107-10. Z Geburtshilfe Neonatol. 0
D. Schneider, G.-F.v. Tempelhoff, D. Hoppenstedt, J. Fareed, L. Heilmann.

---

20. Blood rheology during chemotherapy in patients with ovarian cancer.
1998;90:73-82. Thromb Res. 2.440
G.-F.v. Tempelhoff, F. Niemann, D. Schneider, C. J. Kirkpatrick, G. Hommel, L. Heilmann.

---

19. Chemotherapy and thrombosis (VT) in ovarian malignancy.
1998;11:163–9. Revista Iberoamericana de Thrombosis y Hemostasia. 0
G.-F.v. Tempelhoff, L. Heilmann.

---

18. Hyperviscosity in ovarian malignancy.
1998;82:1104-11. Cancer. 4.771
G.-F.v. Tempelhoff, L. Heilmann, G. Hommel, D. Schneider, F. Niemann, H. Zoller.

---

17. Maternal and cord blood hemostasis at delivery.
1997;25:55-61. J Perinat Med. 1.702
D. Schneider, G.-F.v. Tempelhoff, B. Herrle, L. Heilmann.

---

16. Low - dose Heparin versus niedermolekulares Heparin zur Thromboseprophylaxe in der operativen gynäkologischen Onkologie.
1997;57:1-6. Geburtshilfe Frauenheilkd. 0.823
L. Heilmann, G.-F. v. Tempelhoff, B. Herrle, B. Hojnacki, D. Schneider, H. Ch. Michaelis, H. Wolf.

---

15. Retrospective evaluation of the safety and efficacy of low-molecular-weight heparin as thromboprophylaxis during pregnancy.
1997;177:1567-8. Am J Obstet Gynecol. 3.468
D. Schneider, G.-F. v. Tempelhoff, L. Heilmann.

---

14. Plasmatic plasminogen activator inhibitor activity in patients with primary breast cancer.
1997;77:606-8. Thromb Haemost. 5.044
G.-F.v. Tempelhoff, L. Heilmann, M. Dietrich, D. Schneider, F. Niemann G. Hommel.

---

13. Gerinnungsuntersuchungen und Thromboseinzidenz während der PEC Chemotherapie beim Ovarialkarzinom.
1997; 57:595-601. Geburtshilfe Frauenheilkd. 0.823
G.-F.v. Tempelhoff, F. Niemann, D. Schneider, G. Hommel, L. Heilmann.

---